Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with ...
StockStory.org on MSN3d
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up TodayShares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company ...
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target Discover the Best Stocks and Maximize Your Portfolio: ...
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” ...
Q4 2024 Earnings Call Transcript February 19, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.64, expectations were $0.54. Operator: Ladies and gentlemen, thank you ...
BioMarin Pharmaceutical Inc. ( NASDAQ: BMRN) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ET Traci McCarty - Head of IR Alexander Hardy - President and CEO Brian Mueller - EVP and CFO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback